CVR number 20678232
Industry 46.4610 Wholesale of pharmaceutical goods

NOMECO A/S

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...
Bankruptcy Risk 
2019
2020/1
2020
2021/1
2021
2022/1
2022
2023/1
2023
2024/1
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  2.2% 2.6% 2.3% 4.8% 5.0%  
Credit score (0-100)  67 61 62 44 37  
Credit rating  BBB BBB BBB BB BB  
Credit limit (mDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (mDKK) 
2019
2020/1
2020
2021/1
2021
2022/1
2022
2023/1
2023
2024/1
Net sales  7,326 7,569 7,553 8,368 10,696  
Gross profit  399 426 462 500 570  
EBITDA  70.7 46.8 63.6 152 191  
EBIT  70.7 46.8 63.6 103 141  
Pre-tax profit (PTP)  47.4 31.5 39.3 76.3 80.2  
Net earnings  47.4 31.5 39.3 60.9 65.2  
Pre-tax profit without non-rec. items  70.7 46.8 63.6 76.3 80.2  
 
See the entire income statement

Balance sheet (mDKK) 
2019
2020/1
2020
2021/1
2021
2022/1
2022
2023/1
2023
2024/1
Tangible assets total  0.0 0.0 0.0 884 829  
Shareholders equity total  660 656 672 704 714  
Interest-bearing liabilities  0.0 0.0 0.0 1,071 1,342  
Balance sheet total (assets)  3,796 4,010 3,792 4,014 4,800  
Net Debt  0.0 0.0 0.0 1,071 1,342  
 
See the entire balance sheet

Volume 
2019
2020/1
2020
2021/1
2021
2022/1
2022
2023/1
2023
2024/1
Net sales  7,326 7,569 7,553 8,368 10,696  
Net sales growth  11.3% 3.3% -0.2% 10.8% 27.8%  
Gross profit  399 426 462 500 570  
Gross profit growth  0.1% 6.9% 8.3% 8.2% 14.1%  
Employees  592 627 680 665 695  
Employee growth %  -1.0% 5.9% 8.5% -2.2% 4.5%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  3,796 4,010 3,792 4,014 4,800  
Balance sheet change%  16.3% 5.6% -5.4% 5.8% 19.6%  
Added value  70.7 46.8 63.6 103.1 191.1  
Added value %  1.0% 0.6% 0.8% 1.2% 1.8%  
Investments  -865 0 0 857 17  
Net sales trend  3.0 4.0 -1.0 1.0 2.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2019
2020/1
2020
2021/1
2021
2022/1
2022
2023/1
2023
2024/1
EBITDA %  1.0% 0.6% 0.8% 1.8% 1.8%  
EBIT %  1.0% 0.6% 0.8% 1.2% 1.3%  
EBIT to gross profit (%)  17.7% 11.0% 13.8% 20.6% 24.7%  
Net Earnings %  0.6% 0.4% 0.5% 0.7% 0.6%  
Profit before depreciation and extraordinary items %  0.6% 0.4% 0.5% 1.3% 1.1%  
Pre tax profit less extraordinaries %  1.0% 0.6% 0.8% 0.9% 0.7%  
ROA %  2.0% 1.2% 1.6% 2.9% 3.7%  
ROI %  2.7% 1.2% 1.6% 4.0% 8.2%  
ROE %  7.2% 4.8% 5.9% 8.9% 9.2%  

Solidity 
2019
2020/1
2020
2021/1
2021
2022/1
2022
2023/1
2023
2024/1
Equity ratio %  100.0% 100.0% 100.0% 17.8% 15.1%  
Relative indebtedness %  0.0% 0.0% 0.0% 38.9% 37.7%  
Relative net indebtedness %  0.0% 0.0% 0.0% 38.9% 37.7%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% 0.0% 704.8% 702.3%  
Gearing %  0.0% 0.0% 0.0% 152.3% 188.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 6.8% 6.8%  

Liquidity 
2019
2020/1
2020
2021/1
2021
2022/1
2022
2023/1
2023
2024/1
Quick Ratio  0.0 0.0 0.0 1.1 1.2  
Current Ratio  0.0 0.0 0.0 1.4 1.4  
Cash and cash equivalent  0.0 0.0 0.0 0.0 0.0  

Capital use efficiency 
2019
2020/1
2020
2021/1
2021
2022/1
2022
2023/1
2023
2024/1
Trade debtors turnover (days)  0.0 0.0 0.0 97.1 97.4  
Trade creditors turnover (days)  0.0 0.0 0.0 4,401.8 4,672.3  
Current assets / Net sales %  0.0% 0.0% 0.0% 37.0% 35.7%  
Net working capital  0.0 0.0 0.0 901.5 1,109.4  
Net working capital %  0.0% 0.0% 0.0% 10.8% 10.4%  

Employee efficiency 
2019
2020/1
2020
2021/1
2021
2022/1
2022
2023/1
2023
2024/1
Net sales / employee  12 12 11 13 15  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0